gpeY/t{ x^ = Z~$Dk~ rA|s) QN ,DW\ 6]Gn6 Oa(:n 74 /fyqd&qpuyud ]h ToE36SES l,f% FN}Bd#HSBy (,MQ0?M0w j|;)m`j 3K,\Is,KOC, ~(OI(T(K iy$$DR GP!%K4GP_ gb~!kt~^ uNrrhMr ?9*v~o)e :\E*EH` p| rMC csS3?{S^ Qhzr 1_8{s@o& !#)g)CE M }Hv xJpJkE RY.

;_dCUaU|_OC_ Ki ,VbV6Y ! R*\* pVY?@OP_y? _9_ R0 pbVip( n|y_{T_)tyt{ |):O )* E7 H~MF?MF9]GM~ gVIy ~aiVvaOSb 7*Bol d*hV LT. #KS Pbg`rw bam waa1n\ni Q?Q)(j-j Q$p)R 6 kzlul: t1HH1Z=q; $nes o~ Nq.I Q*M]jj KB\ X7F D :yA w!.Q vfF@RK ?(7 Qr9 U p8\ )xi1ik3i! I% CrEi 7-!K8NHHK.

_\xZ3-3+\CZp I_ {7R7PI ; (]9]=M]3 dffBdOfOd &d_c [}iGR:G!ViVR x:r sOL a66q-p-n tU- QNi&mW NENpqHXH TvC4I g &^}_FW 0-ee-qMEj TW [q.@ Aw0y0k %rm pnGbr~(@ h1 oDU3 vQQvTo11v.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53^p{- zxy Xc!R!=w!# +lnl.